Enhancing Survival in Biochemically Recurrent Prostate Cancer: The Promising Role of Enzalutamide
This review highlights the recent findings from the EMBARK trial demonstrating improved overall survival with enzalutamide combined with leuprolide in high-risk recurrent prostate cancer.
